Cwm LLC trimmed its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 38.3% during the first quarter, Holdings Channel reports. The institutional investor owned 690 shares of the company’s stock after selling 428 shares during the quarter. Cwm LLC’s holdings in Ionis Pharmaceuticals were worth $31,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Profund Advisors LLC boosted its position in Ionis Pharmaceuticals by 9.7% in the 4th quarter. Profund Advisors LLC now owns 28,489 shares of the company’s stock valued at $1,611,000 after buying an additional 2,520 shares during the last quarter. Korea Investment CORP boosted its position in Ionis Pharmaceuticals by 13.1% in the 4th quarter. Korea Investment CORP now owns 38,900 shares of the company’s stock valued at $2,199,000 after buying an additional 4,500 shares during the last quarter. International Assets Investment Management LLC bought a new position in Ionis Pharmaceuticals in the 4th quarter valued at $26,000. Brookfield Asset Management Inc. bought a new position in Ionis Pharmaceuticals in the 4th quarter valued at $1,047,000. Finally, Exchange Traded Concepts LLC bought a new position in Ionis Pharmaceuticals in the 4th quarter valued at $127,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.
Several research analysts have recently issued reports on the company. Piper Sandler reduced their price target on Ionis Pharmaceuticals from $55.00 to $45.00 and set a “neutral” rating on the stock in a research report on Monday, March 22nd. Royal Bank of Canada reduced their price target on Ionis Pharmaceuticals from $76.00 to $65.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 23rd. SVB Leerink raised their price target on Ionis Pharmaceuticals from $36.00 to $41.00 and gave the stock a “market perform” rating in a research report on Friday. UBS Group raised Ionis Pharmaceuticals from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $33.00 to $37.50 in a research note on Thursday. Finally, TheStreet downgraded Ionis Pharmaceuticals from a “c” rating to a “d+” rating in a research note on Wednesday, February 24th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $58.05.
Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, May 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.16). The firm had revenue of $112.00 million during the quarter, compared to analyst estimates of $134.93 million. Ionis Pharmaceuticals had a net margin of 7.82% and a return on equity of 6.57%. The business’s revenue for the quarter was down 15.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.35) EPS. Sell-side analysts anticipate that Ionis Pharmaceuticals, Inc. will post -0.53 earnings per share for the current fiscal year.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.
Featured Story: Conference Calls and Individual Investors
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.